Paper Details

  1. Home
  2. Paper Details

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Author: CampionLoïc, MauboussinMarie-Hélène, PacteauValérie, PeinFrançois, RioEmmanuel, SupiotStephane

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explored the role of salvage pelvic image-guided intensity-modulated radiation therapy (IMRT) combined with androgen-deprivation therapy (ADT) in prolonging the failure-free interval between ADT courses or even achieving a cure in selected patients with limited metastatic burden of oligometastatic prostate cancer.
Paper Details　
Original Abstract of the Article :
Metastatic prostate cancer remains a common cause of death in Europe, and improvements in management of the disease are urgently needed. The advent of positron-emission tomography (PET) imaging enhanced with fluorocholine has led to the identification of a new sub-group of metastatic prostate cancer...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582833/

データ提供：米国国立医学図書館（NLM）

Combating Prostate Cancer: A Multimodal Approach

Imagine a valiant warrior battling a formidable foe, with a multi-pronged strategy. Prostate cancer, a complex and challenging disease, requires a comprehensive approach to treatment. This study explores a multimodal treatment strategy for patients with oligometastatic pelvic node relapses of prostate cancer. The study involves a phase II clinical trial, investigating the combination of salvage radiotherapy and hormone therapy. The researchers aim to determine the effectiveness of this combined approach in prolonging the time between hormone therapy cycles and potentially achieving a cure in selected patients.

A New Frontier in Prostate Cancer Treatment

This study presents a novel approach to treating prostate cancer, particularly for patients with oligometastatic disease. The combination of salvage radiotherapy and hormone therapy holds potential for improving treatment outcomes and extending survival.

Optimizing Treatment: A Personalized Approach

The findings of this study highlight the importance of personalized treatment approaches for prostate cancer. This multimodal strategy, combining different therapies, can be tailored to individual patients' needs and disease characteristics, potentially leading to more effective and individualized outcomes.

Dr. Camel's Conclusion

Just as a desert traveler navigates a challenging landscape, treating prostate cancer requires a multifaceted approach. This study offers a glimmer of hope for patients with oligometastatic disease, suggesting that a combination of therapies can effectively manage this complex condition.

Date :
  1. Date Completed 2016-07-01
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26408012

DOI: Digital Object Identifier

PMC4582833

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.